Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
September 07 2021 - 5:20PM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need in
oncology and infectious diseases with a current focus on breast
cancer and COVID-19, has adjourned today’s special stockholder
meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow
additional time for stockholders to vote. The Company urges
stockholders to vote on the proposal put forth in the proxy
statement prior to the new meeting date.
The purpose of the special meeting is to approve an increase in
authorized shares of common stock, which requires the affirmative
vote of a majority of the shares of common stock issued and
outstanding as of the record date. While the votes cast to date
have been strongly in favor of the proposal (73% of shares voted
have been voted in favor), only 58% of the outstanding shares of
common stock have been voted with 42% voting in favor of the
proposal. Atossa is therefore adjourning the meeting for 30 days to
allow additional time for stockholders to vote.
Leading proxy advisory firms ISS and Glass Lewis have
recommended stockholders vote in favor of the proposed increase in
authorized shares.
The newly authorized shares of common stock are primarily
intended to be used to complete and/or support acquisitions,
collaborations, partnerships and licensing transactions. If the
proposal is approved by the stockholders, Atossa does not intend to
issue any of the newly authorized shares of common stock for the
purpose of raising capital in the nine months following approval of
the proposal at a price less than $10 per share.
Details of the proposal, the stockholder meeting, and additional
information on how to vote your shares can be found in the proxy
statement, available here:
https://www.sec.gov/Archives/edgar/data/1488039/000143774921019134/atos20210809_def14a.htm
Atossa stockholders may vote by calling
(833) 786-6488 Monday through
Friday 9 a.m. to 9 p.m. Eastern Time.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need in oncology and infectious
diseases with a current focus on breast cancer and COVID-19. For
more information, please visit www.atossatherapeutics.com.
Forward-Looking Statements Disclaimer
Statement
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including,
without limitation, statements regarding the risks and
uncertainties associated with any variation between interim and
final clinical results, actions and inactions by the FDA, the
outcome or timing of regulatory approvals needed by Atossa
including those needed to commence studies of AT-H201, AT-301 and
Endoxifen, lower than anticipated rate of patient enrollment,
estimated market size of drugs under development, the safety and
efficacy of Atossa’s products, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in breast density, reduction of Ki-67 or any other result
from a neoadjuvant study is an approvable endpoint for oral
Endoxifen, and other risks detailed from time to time in Atossa’s
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and
General CounselOffice: (866) 893-4927kyle.guse@atossainc.com
Investor Relations Contact:Core IROffice:(516)
222-2560ir@atossainc.comSource: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024